COVID icon
Fibrosis and COVID-19

Fibrosis is a major cause of mortality, with global death rates increasing in recent years. Whether genetic-related, malignant, infectious, autoimmune, or idiopathic, fibrosis can affect any organ.

Lung fibrosis poses a particular clinical issue due to the lack of effective therapies and poor understanding of its aetiology. With respect to the pathogenesis of fibrosis, attention has focussed on fibroblast activation, given its central role in the synthesis of collagen and other extracellular matrix proteins.

In this study, the authors used snRNA-sequencing in fixed tissue sections from patients suffering from Coronavirus Disease 2019 (COVID-19), and identified a ‘COVID‑19 signature’ in the lung ecosystem, consisting mainly of five molecular and cellular events:

  1. Monocyte/macrophage-derived IL‑1β and epithelial-derived IL‑6 production
  2. Impaired alveolar type 1 (AT1) regeneration
  3. Destruction of alveolar epithelium
  4. Expansion of JUN+ CTHRC1+ pathological fibroblasts
  5. Presence of ectopic tuft-like cells

The authors suggest that these mechanisms are likely triggers to pulmonary fibrosis and contribute to COVID‑19 fatality. They identified a reduction in alveolar type II (AT2) and type I (AT1) cells and an increase in monocytes/macrophages, fibroblasts, and neuronal cells.

Their data suggested an impaired T‑cell response in COVID‑19, although no significant increase in T‑cell count was found.

Further analysis revealed that monocyte-derived macrophages (MDMs), transitioning MDMs and resident macrophages were more frequent, highly, and aberrantly activated in COVID‑19.

The numbers of Tuft-like cells (ChAT+ or POU2F3+) were increased 3-fold in the upper airways, and they were ectopically present in the lung parenchyma of COVID‑19 patients, but not in control lungs.

αSMA immunohistochemistry revealed that fibroblasts were significantly increased in COVID‑19 lungs. Likewise, Sirius red staining and degree of fibrosis correlated with disease duration, indicating ensuing lung fibrosis over time in COVID‑19.

Different fibroblasts subtypes were identified: alveolar, adventitial, pathological, and intermediate pathological, and expansion of JUN++ CTHRC1+ pathological fibroblasts (pFB) was observed.

These pFB are critical drivers of lung fibrosis in murine models and in patients with idiopathic pulmonary fibrosis (IPF). Their increased frequency suggests pFB has a role in promoting rapidly evolving fibrosis in COVID‑19.

The authors also explored ligand-receptor interactions using CellPhoneDB across all major cell types and identified TGF‑β/STAT‑3/Jun signalling implicated in lung fibrosis.

The results of this study substantially extend previous publications by providing new insights into lung fibrosis and COVID‑19 pathophysiology. Significantly, the atlas provides a cellular landscape that will be a useful resource for therapeutic development.

Reference

Melms, J.C., Biermann, J., Huang, H. et al. A molecular single-cell lung atlas of lethal COVID-19. Nature (2021)
doi: 10.1038/s41586-021-03569-1

Want to ask a question about

COVID‑19, Immunohistochemistry or Fibrosis?

histology icon
Epistem's Sequencing, IHC and Imaging Services

Epistem is a GCLP-accredited laboratory specialising in providing biomarker, target discovery and personalised medicine information. We offer microarray, qPCR and NGS services (including the 10X genomics platform for single-cell sequencing) for gene expression, whole-genome, and epigenetic analysis in all species. Our team can help you on your COVID‑19 and lung fibrosis-related enquiries.

The Histology and Immunohistochemistry team at Epistem have a wealth of experience in developing IHC protocols for a range of biological targets. Our deep understanding of IHC methodology has allowed us to develop and troubleshoot hundreds of working protocols for both automated (Ventana Discovery Ultra) and manual applications. We offer a bespoke service which can be suited to your project. We can work readily with FFPE, frozen tissues, with chromogenic and fluorescent detection systems as well as RNAScope methodologies.

About Epistem

Epistem's contract research service is committed to providing reliable, innovative and transferable pre-clinical models and services to support decision making throughout the drug discovery and development pipeline.

Tel: +44 (0)161 850 7600  Email: info@epistem.co.uk